Standout Papers

Guidelines for the Evaluation of Immune Therapy Activity in... 1999 2026 2008 2017 2.3k
  1. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009)
    Jedd D. Wolchok, Axel Hoos et al. Clinical Cancer Research
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (2015)
    Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology
  3. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab (2012)
    Jeffrey S. Weber, Katharina C. Kähler et al. Journal of Clinical Oncology
  4. Mucosal flora in inflammatory bowel disease (2002)
    Alexander Swidsinski, Axel Ladhoff et al. Gastroenterology
  5. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients (1999)
    Peter P. Lee, Cassian Yee et al. Nature Medicine
  6. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  7. Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2 (1994)
    Steven A. Rosenberg, John R. Yannelli et al. JNCI Journal of the National Cancer Institute
  8. Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease (2005)
    Alexander Swidsinski, Jeffrey S. Weber et al. Journal of Clinical Microbiology
  9. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes (2015)
    Morganna Freeman-Keller, Young‐Chul Kim et al. Clinical Cancer Research
  10. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
    Omid Hamid, Caroline Robert et al. Annals of Oncology
  11. Toxicities of Immunotherapy for the Practitioner (2015)
    Jeffrey S. Weber, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  12. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma (2018)
    Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine
  13. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013)
    Jedd D. Wolchok, F. Stephen Hodi et al. Annals of the New York Academy of Sciences
  14. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies (2021)
    Ryan J. Sullivan, Jeffrey S. Weber Nature Reviews Drug Discovery

Immediate Impact

46 by Nobel laureates 27 from Science/Nature 255 standout
Sub-graph 1 of 14

Citing Papers

Functional T cells are capable of supernumerary cell division and longevity
2023 StandoutNature
Tertiary lymphoid structures in cancer
2022 StandoutScience
45 intermediate papers

Works of Jeffrey S. Weber being referenced

Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
2016
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
2012
and 21 more

Author Peers

Author Last Decade Papers Cites
Jeffrey S. Weber 22636 15432 10025 507 33.5k
Thomas F. Gajewski 19392 20433 11602 319 35.1k
Ignacio Melero 15374 16403 6438 384 27.3k
John B.A.G. Haanen 13487 10645 6599 424 23.0k
Elizabeth M. Jaffee 18074 15555 9061 376 29.9k
Ton N. Schumacher 17479 22341 9526 309 33.5k
John M. Kirkwood 30784 18585 17591 679 45.4k
F. Stephen Hodi 33441 16392 10242 509 42.8k
Dirk Schadendorf 26861 15219 20959 966 45.3k
George Coukos 17255 16776 12693 392 34.6k
Reinhard Dummer 21952 14420 18795 940 43.0k

All Works

Loading papers...

Rankless by CCL
2026